Adam Schayowitz - 09 Apr 2026 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: EVP, Head of Research & Development
Issuer ticker: ZYME
Reported as of: 09 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Apr 2026, 16:10:04 UTC
Source filing: View source filing
Reporting owner signature: /s/ Catherine Graham, Attorney-in-Fact

Key filing fact

Adam Schayowitz filed Form 4 for Zymeworks Inc. (ZYME) on 10 Apr 2026.

Key facts

This page summarizes Adam Schayowitz's Form 4 filing for Zymeworks Inc. (ZYME).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 10 Apr 2026, 16:10.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127119 Primary reporting owner

Schayowitz Adam

Relationship: EVP, Head of Research & Development
Address: C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature: /s/ Catherine Graham, Attorney-in-Fact
Signature date: 10 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +70,000
Change %
Price: $0.000000^*
Shares after: 70,000
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $27.35
Footnotes: F1

ZYME transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +47,000
Change %
Price: $0.000000^*
Shares after: 47,000
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,000
Exercise price
Footnotes: F2, F3

ZYME transaction Derivative

Performance Stock Unit

Award

Transaction value
Shares: +76,000
Change %
Price: $0.000000^*
Shares after: 76,000
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 76,000
Exercise price
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

Footnote F2

Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

Footnote F3

RSUs vest in four equal annual installments beginning on first anniversary of grant date.

Footnote F4

Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.

Footnote F5

(Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).

SEC remarks

EVP, Head of Research & Development